V

Viking Therapeutics
D

VKTX

28.150
USD
0.43
(1.55%)
مغلق
حجم التداول
45,463
الربح لكل سهم
-2
العائد الربحي
-
P/E
-24
حجم السوق
3,161,513,692
أصول ذات صلة
A
ABUS
0.05000
(1.57%)
3.24000 USD
ALNY
ALNY
-4.39
(-1.33%)
325.26 USD
A
ARWR
-0.120
(-0.71%)
16.790 USD
C
CRBP
-0.15750
(-2.03%)
7.60000 USD
MRNA
MRNA
0.195
(0.64%)
30.480 USD
V
VKTX
0.430
(1.55%)
28.150 USD
المزيد
الأخبار المقالات

العنوان: Viking Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.